Last reviewed · How we verify
Carboplatin, Etoposide, Ifosfamide
This combination of three chemotherapy agents works by damaging DNA and preventing cancer cell division through different mechanisms: carboplatin and ifosfamide cross-link DNA strands, while etoposide inhibits topoisomerase II.
This combination of three chemotherapy agents works by damaging DNA and preventing cancer cell division through different mechanisms: carboplatin and ifosfamide cross-link DNA strands, while etoposide inhibits topoisomerase II. Used for Germ cell tumors, Small cell lung cancer, Lymphomas.
At a glance
| Generic name | Carboplatin, Etoposide, Ifosfamide |
|---|---|
| Sponsor | University Hospital Muenster |
| Drug class | Combination chemotherapy regimen |
| Target | DNA (multiple mechanisms: alkylation, cross-linking, topoisomerase II inhibition) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Carboplatin is a platinum-based alkylating agent that forms DNA adducts and cross-links, preventing DNA replication. Ifosfamide is an alkylating agent that similarly damages DNA through cross-linking. Etoposide is a topoisomerase II inhibitor that prevents DNA unwinding and repair. Together, these agents create multiple pathways of DNA damage to kill rapidly dividing cancer cells.
Approved indications
- Germ cell tumors
- Small cell lung cancer
- Lymphomas
- Sarcomas
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Alopecia
- Mucositis
- Hemorrhagic cystitis (ifosfamide-related)
- Nephrotoxicity
- Neurotoxicity
- Secondary malignancies
Key clinical trials
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (PHASE1, PHASE2)
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (PHASE1, PHASE2)
- Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma (PHASE3)
- A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT (PHASE2)
- A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT (PHASE2)
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (PHASE2, PHASE3)
- N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carboplatin, Etoposide, Ifosfamide CI brief — competitive landscape report
- Carboplatin, Etoposide, Ifosfamide updates RSS · CI watch RSS
- University Hospital Muenster portfolio CI